Spero Therapeutics, Inc. (SPRO) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	43.0M	59.6M	48.0M	103.8M	48.6M
Cost of Revenue	—	—	96.8M	51.4M	—
Gross Profit	43.0M	59.6M	(48.8M)	52.3M	48.6M
Operating Expenses
R&D Expense	20.5M	38.5M	96.8M	51.4M	47.6M
SG&A Expense	19.9M	21.2M	23.7M	25.6M	36.5M
General & Admin Expense	19.9M	21.2M	22.9M	25.0M	36.5M
Selling & Marketing Expense	—	—	792.0K	566.0K	—
Other Expenses	(3.4M)	—	(95.9M)	(46.1M)	6.7M
Total Operating Expenses	36.9M	59.6M	24.6M	30.9M	90.8M
Cost and Expenses	36.9M	59.6M	121.3M	82.3M	90.8M
Operating Income (EBIT)	6.0M	(24.0K)	(73.4M)	21.5M	(42.2M)
Non-Operating
Interest Income	1.6M	2.5M	4.7M	3.9M	1.1M
Interest Expense	—	—	—	—	2.6M
Net Interest Income	1.6M	2.5M	4.7M	3.9M	(1.5M)
Other Non-Op Income/Expense	1.6M	8.9M	4.8M	3.9M	(4.2M)
Non-Operating Income (excl Interest)	(1.7M)	(8.9M)	(877.0K)	(5.3M)	1.6M
EBT (Pre-Tax Income)	7.6M	8.8M	(68.6M)	25.4M	(46.4M)
Income Tax Expense	261.0K	261.0K	—	2.6M	—
Bottom Line
Net Income	7.4M	8.6M	(68.6M)	22.8M	(46.4M)
Earnings from Cont. Ops	7.4M	8.6M	(68.6M)	22.8M	(46.4M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	7.4M	8.6M	(68.6M)	22.8M	(46.4M)
Per Share
Basic EPS	$0.14	$0.15	($1.27)	$0.43	($1.23)
Diluted EPS	$0.11	$0.15	($1.27)	$0.43	($1.23)
Revenue Per Share	$0.74	$1.06	$0.89	$1.97	$1.29
Shares
Basic Shares Outstanding	58.0M	56.0M	54.0M	52.7M	37.6M
Diluted Shares Outstanding	58.0M	59.0M	54.0M	53.0M	37.6M
Profitability Metrics
EBITDA	7.7M	8.8M	(72.5M)	27.2M	(42.9M)
D&A	500.00	—	2.0K	367.0K	869.0K
EBIT	7.7M	8.8M	(72.5M)	26.8M	(43.8M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026